Research Status Of Treatment For Advanced Renal Cell Carcinoma By Tyrosine Kinase Inhibitors

Renal cell carcinoma(RCC) is renal cancer originated from urinarytubule system with a high morbidity of2%～3%in adults malignancies and80%～90%in adult kidney malignancies. The rich blood supply of kidneyleaded to the high metastatic of RCC in early stage with25%RCC patientshave tumor metastasis and a large part of that was found in patients withnewly diagnosed. Treatment of advanced RCC has important implicationsfor prognosis and quality of life of patients as the number of patients diedof RCC increased every year. In recent years, along with in-depthunderstanding of the biology and molecular pathogenesis of RCC,especially in terms of deepening the study of molecular signaling pathways,targeted therapy in the treatment of advanced RCC has shown significantadvantages, especially a variety of tyrosine kinase inhibitor is widely usedin the clinical treatment of renal cell carcinoma, effectively improve theprognosis of patients with advanced RCC. Tyrosine kinase inhibitorsare enzymatic receptor proteins which catalyse the transfer ofphosphate from ATP to tyrosine present in the peptides. They are involvedin the proliferation, angiogenesis, and invasiveness of the tumour. Thisarticle will expound the principles to treat the advanced RCC by the tyrosine kinase inhibitor, as well as the therapeutic effect and safety oftreatment of the various tyrosine kinase inhibitors for the advanced RCC. Itwill discuss the research status of tyrosine kinase inhibitor for the treatmentof advanced RCC, and help clinicians to develop better treatments.